

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005

## AMENDMENT


### In the claims:

Please amend claims 1, 31, 32, and 58 as shown in the following Listing of the Claims.

### Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising, in addition to one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, ~~a selective COX-2 inhibitor~~, or a non-steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof,

between 0.01 per cent and 60 per cent by weight of a compound of formula I



with n and m > 18 and < 46 and with a molecular weight between about 600 and about 18,000, in combination with 0.01% to 20% by weight of phosphatidylcholine, for enhancement of active-ingredient absorption.

2. (Canceled)

3. (Previously presented) A pharmaceutical composition according to claim 1 with 0.1 per cent to 30 per cent by weight of the compound of formula I with n and m > 24 and < 36 and with the molecular weight between 1,000 and 4,000.

4. (Previously presented) A pharmaceutical composition according to claim 1, wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005

5-12. (Canceled)

13. (Previously presented) A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in Claim 1 to a patient in need thereof, wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.

14. (Canceled)

15. (Previously presented) A pharmaceutical composition according to Claim 3, wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.

16-17. (Canceled)

18. (Previously presented) The composition according to Claim 1, wherein trans- absorption of the active ingredient is increased by up to more than five times its normal value.

19. (Previously presented) The composition according to Claim 3, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Previously presented) A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in Claim 3 to a patient in need thereof, wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005

24. (Canceled)

25. (Previously presented) A pharmaceutical composition as claimed in Claim 1, wherein trans-absorption of the active ingredient is increased by up to more than ten times its normal value.

26. (Previously presented) A pharmaceutical composition as claimed in Claim 1, wherein trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.

27. (Previously presented) A method as claimed in Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than ten times its normal value.

28. (Previously presented) A method as claimed in Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.

29. (Previously presented) A pharmaceutical composition as claimed in Claim 1, wherein the active ingredient is troxerutine.


30. (Previously presented) A method as claimed in Claim 13, wherein the active ingredient is troxerutine.

31. (Currently amended) A pharmaceutical composition consisting essentially of:

(1) one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, ~~a selective COX-2 inhibitor~~, or a non-steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof;

(2) between about 0.01 per cent and about 60 per cent by weight of a compound of formula I

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005




wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;

- (3) phosphatidylcholine;
- (4) optionally tocopherol acetate;
- (5) optionally polyacrylamide, C13-C14 isoparaffin, and laureth-7;
- (6) optionally methyl-p-hydroxybenzoate;
- (7) optionally propyl-p-hydroxybenzoate;
- (8) optionally phenoxyethanol;
- (9) optionally nor-chenodeoxycolic acid;
- (10) optionally transcitol; and
- (11) optionally water.

32. (Currently amended) A pharmaceutical composition consisting essentially of:

(1) one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, ~~a selective COX-2 inhibitor~~, or a non-steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof,;

(2) between about 0.01 per cent and about 60 per cent by weight of a compound of formula I



wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;

- (3) phosphatidylcholine;
- (4) optionally tocopherol acetate;
- (5) optionally polyacrylamide, C13-C14 isoparaffin, and laureth-7;

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005

- (6) optionally methyl-p-hydroxybenzoate;
- (7) optionally propyl-p-hydroxybenzoate;
- (8) optionally phenoxyethanol;
- (9) optionally nor-chenodeoxycolic acid;
- (10) optionally transcitol;
- (11) optionally lactic acid;
- (12) optionally ethyl alcohol; and
- (13) optionally water.

33. (Previously presented) A pharmaceutical composition as claimed in Claim 31, wherein the active ingredient is troxerutine.

34. (Previously presented) A pharmaceutical composition according to claim 31, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.

35. (Previously presented) A pharmaceutical composition according to claim 33, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.

36. (Previously presented) A pharmaceutical composition as claimed in Claim 32, wherein the active ingredient is troxerutine.

37. (Previously presented) A pharmaceutical composition according to claim 32, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.

38. (Previously presented) A pharmaceutical composition according to claim 36, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the

618156-1 Festo Response to USSN 09/673,411 Response mailed Oct 26, 2005

formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.

39. (Previously presented) The method according to Claim 13, wherein the active ingredient is Troxerutine, Nimesulide, Ketoprofen, Etodolic Acid, or a combination thereof.

40. (Previously presented) The pharmaceutical composition as claimed in Claim 1, wherein the active ingredient is Troxerutine, Nimesulide, Ketoprofen, Etodolic Acid, or a combination thereof.

41. (Previously presented) The pharmaceutical composition as claimed in Claim 31, wherein the active ingredient is Troxerutine, Nimesulide, Ketoprofen, Etodolic Acid, or a combination thereof.

42. (Previously presented) The pharmaceutical composition as claimed in Claim 32, wherein the active ingredient is Troxerutine, Nimesulide, Ketoprofen, Etodolic Acid, or a combination thereof.

43. (Previously presented) The pharmaceutical composition as claimed in Claim 1, wherein phosphatidylcholine is 0.01% to 10% by weight of the pharmaceutical composition.

44 - 57 (Canceled)

58. (Currently amended) The pharmaceutical composition as claimed in claim 31, wherein the composition consists essentially of the one or more active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, a selective COX-2 inhibitor, or a non-steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof, the compound formula I, the phosphatidylcholine, and optionally the water.

59. (Previously presented) A method according to Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.